Global Organ Preservation Solution Industry - Reportlinker Review

News provided by

Reportlinker

21 Oct, 2015, 05:08 ET

NEW YORK, Oct. 21, 2015 /PRNewswire/ -- This report analyzes the worldwide markets for Organ Preservation Solutions in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 21 companies including many key and niche players such as -

21st Century Medicine
BioLife Solutions, Inc.
Claris Injectables Limited
Dr. Franz Köhler Chemie GmbH
Essential Pharmaceuticals, LLC



Read the full report: http://www.reportlinker.com/p0209264-summary/view-report.html



I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1 Disclaimers.............. I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW.............. II-1 A Prelude.............. II-1 Current & Future Market Analysis II-1 Geographic Landscape..............II-1 Competitive Scenario..............II-2 Table 1: Global Organ Preservation Solutions Market (2011 & 2015): Percentage Breakdown of Dollar Sales for Perfadex, Hypo Thermosol, Custodiol® HTK, Renograf, Viaspan, and Others (includes corresponding Graph/Chart) II-2 Custodiol HTK Gains Prominence vs. the Gold Standard UW Solution II-3 Contamination Concerns with Regard to ViaSpan® II-3 Organ Preservation Techniques..............II-3 Simple Cold Storage..............II-4 Continuous Hypothermic Perfusion/Hypothermic Perfusion Preservation.............. II-4

2. MARKET TRENDS AND GROWTH DRIVERS..............II-5 EVLP: Revolutionary Technique for Lung Preservation II-5 New Paradigms in Heart and Lung Preservation II-5 Organ Banking: Glimpse into the Future? II-6 Preservation Solutions - A Key to Deceased Donor Transplants II-6 Euro-Collins Extending Opportunities in the Kidney Segment II-7 Cardiac Preservation Scenario Remains Static II-7 Lungs Preservation in Search of Ideal Solution II-7 Scientists See Cryopreservation as a Potential Means for Organ Preservation.............. II-7 Measures to Address Organ Shortage to Infuse Demand for Preservation Solutions..............II-8 Europe and the United States Lead the Global Organ Transplants Market.............. II-8 Table 2: Global Organ Transplants by Leading Country in Terms of No. of Transplants Per Million Population (PMP) for the Year 2012 (includes corresponding Graph/Chart) II-9 Living Donors on the Rise..............II-9 Table 3: Global Living Organ Donors by Leading Country in Terms of No. of Donors Per Million Population (PMP) for the Year 2013 (includes corresponding Graph/Chart) II-10

Table 4: Global Deceased Organ Donors by Leading Country in Terms of No. of Donors Per Million Population (PMP) for the Year 2013 (includes corresponding Graph/Chart) II-10 Graying Population and Chronic Diseases Surge Need for Transplants.............. II-11 Table 5: Elderly Population (65+ Years) as a % of Total Population (2000 & 2025P) (includes corresponding Graph/Chart).............. II-11 Transplant Tourism - Creating Brighter Avenues II-11 Combined Organ Transplantation - Gaining Attention II-12 Table 6: Multiple Organ Transplants in the US - No. of Transplants by Type (2010-2015) II-12 Cardiac Arrest Death Patients - The Untapped Potential Donors II-12 Table 7: Leading Countries in Terms of Number of Donors after Cardiac Death (DCD): 2013 (includes corresponding Graph/Chart).............. II-13

3. PRODUCT OVERVIEW.............. II-14 Organ Preservation Solutions..............II-14 Elements and Functions of Organ Preservation Solutions II-14 Technical Specifications of the Organ Preservation Solutions II-14 Solutions in Concentrated Form II-14 Steps in Organ Preservation..............II-15 Identification of the Donor..............II-15 Organ Removal.............. II-15 Organ Recovery and Preservation II-15 Organ Preservation Techniques..............II-15 Hypothermia.............. II-15 Requirements of Ideal Preservation Solution II-16 Factors Determining Organ Viability II-16 Storage Duration Time..............II-16 Storage Time Period for Organs and Tissues II-17 Factors Impacting the Organ Preservation II-17 Hypothermia Induced Cell Swelling II-17 Cellular Acidosis and ATP Usage II-17 Compromised Membrane Function II-18 Functions of Organ Preservation Solutions II-18 Prevention of Reactive Oxygen Species Formation II-18 Reduction of Cell Swelling..............II-19 Prevention of Cellular Acidosis II-19 Benefits with Colloids..............II-20 Secondary Functions..............II-20 Production and Packaging..............II-21 Production.............. II-21 Packaging.............. II-21 Tests for Organ Preservation Solutions II-21 Hydroxymethylfurfural Test..............II-21 Particulate Contamination..............II-21 Test for Pyrogens..............II-21 Static Cold Storage - The Most Applied and Popular Technique II-22 Vitrification - A Promising Cryopreservation Approach for Whole Organs.............. II-22 Select Products.............. II-22 Euro Collins Solution..............II-22 Composition of Euro-Collins Solution II-22 University of Wisconsin (UW) Solution II-23 Composition of UW Solution..............II-23 Custodiol® Histidine-Tryptophan-Ketoglutarate (HTK) Solution II-24 Composition of Custodial HTK Solution II-24 Advantages.............. II-24 Disadvantages.............. II-24 Major Clinical Differences between Custodiol HTK and Viaspan II-25 Celsior Solution.............. II-25 Composition of Celsior Solution II-25 Hypothermosol.............. II-26 Perfadex®.............. II-26 Advantages.............. II-26 Ross-Marshall Citrate Solutions II-26 Phosphate-Buffered Sucrose Solution II-26 Lifor.............. II-27 IGL-1.............. II-27 HBS Solution.............. II-27 ET-Kyoto.............. II-27 Composition of ET-Kyoto Solution II-27 Polysol.............. II-28 TranSend.............. II-28 Background.............. II-28 Organ Transplantation..............II-29 A Prelude.............. II-29 Heart Transplantation..............II-29 Heart Diseases and Disorders II-29 Post-Operative Complications and Consequences of Heart Transplants.............. II-30 Kidney Transplantation..............II-30 Kidney Disorders and Diseases..............II-30 Donor Evaluation..............II-30 Waiting List.............. II-31 Surgery/Post-Operation..............II-31 Post-Operative Supervision and Issues II-31 Liver Transplantation..............II-31 Liver Disorders and Diseases II-32 Pancreas Transplantation..............II-32 Post-Operative Complications and Consequences of Pancreas Transplants.............. II-33 Small Intestine Transplantation II-33 Intestine Disorders and Diseases II-34 Heart-and-Lung Transplantation..............II-34 Lung Transplantation..............II-34 Lung Diseases and Disorders..............II-34 Lung Patients Survival Statistics II-34 Transplantation Immunology..............II-35 Acute Cellular Rejection..............II-35 Chronic Rejection.............. II-35 Post-Transplant Observations..............II-35 Types of Donors.............. II-36 Alive Donors.............. II-36 Related Donors.............. II-36 Good Samaritans.............. II-36 Rewarded/Forced Donors..............II-36 Deceased Donors.............. II-36 Directed / Allocated..............II-37 Organs Transplanted by Type of Donor II-37 Organ Donation and Eligibility Criteria II-37 Factors Considered for Matching Recipients to Donor Organs II-37 Testing.............. II-38 Blood Typing.............. II-38 Tissue Typing.............. II-38 Issues Impacting Transplantation Market II-38 Scarcity of Donor Organs..............II-38 Organ Rejection.............. II-38 Other Issues.............. II-39 Ethical Concerns and Bioethical Issues II-39 Lack of Requisite Expertise..............II-39 Transplantation - Safety Requirements II-39 Waiting List.............. II-40 Active Waiting List Patients II-40 Inactive Waiting List Patients II-40 Transplantation Expenses..............II-40 Major Medical and Non-Medical Expenses II-41 Major Milestones in Organ Transplantation II-41

4. RECENT INDUSTRY ACTIVITY..............II-42 Paragonix Technologies Announces Publication of Sherpa Pak™ Transport Systems..............II-42 CFDA Approves Organ Preservation Solutions by Lifeline Scientific II-42 Provepharm Enters Into Partnership with DFKC II-42 HEMARINA Signs Contract with LFB Biomanufacturing II-42 HEMARINA Establishes Operations in the US II-42

5. FOCUS ON SELECT KEY PLAYERS..............II-43 21st Century Medicine (US)..............II-43 BioLife Solutions, Inc. (US)..............II-43 Claris Injectables Limited (India) II-44 Dr. Franz Köhler Chemie GmbH (Germany) II-44 Essential Pharmaceuticals, LLC (US) II-44 Lifeline Scientific (US)..............II-45 Preservation Solutions, Inc. (US) II-45 XVIVO Perfusion AB (Sweden)..............II-45

6. GLOBAL MARKET PERSPECTIVE..............II-46 Table 8: World Recent Past, Current & Future Analysis for Organ Preservation Solutions by Geographic Region - US, Canada, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart).............. II-46

Table 9: World Historic Review for Organ Preservation Solutions by Geographic Region - US, Canada, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 through 2013 (includes corresponding Graph/Chart) II-47

Table 10: World 14-Year Perspective for Organ Preservation Solutions by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Europe, Asia-Pacific, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)..............II-48

III. MARKET

1. THE UNITED STATES.............. III-1 A.Market Analysis.............. III-1 Increasing Number of Organ Transplants Drives the Organ Preservation Market..............III-1 Table 11: The US Kidney Transplants by Donor Type - Deceased and Living: Number of Procedures for 2013, 2014, and 2015 (As of Sept) (includes corresponding Graph/Chart) III-1

Table 12: The US Liver Transplants by Donor Type - Deceased and Living: Number of Procedures for 2013, 2014, and 2015 (As of Sept, 2015) (includes corresponding Graph/Chart) III-2

Table 13: The US Heart Transplants by Donor Type - Deceased and Living: Number of Procedures for 2013, 2014, and 2015 (As of Sept, 2015) (includes corresponding Graph/Chart) III-2

Table 14: The US Lung Transplants by Donor Type - Deceased and Living: Number of Procedures for 2013, 2014, and 2015 (As of Sept, 2015) (includes corresponding Graph/Chart) III-3

Table 15: The US Pancreas Transplants by Donor Type - Deceased and Living: Number of Procedures for 2013, 2014, and 2015 (As of Sept, 2015) (includes corresponding Graph/Chart).............. III-3

Table 16: The US Intestinal Transplants by Donor Type - Deceased and Living: Number of Procedures for 2013, 2014, and 2015 (As of Sept, 2015) (includes corresponding Graph/Chart).............. III-4 Ever-Increasing Waiting Lists Create Demand for Proper Organ Preservation.............. III-4 Table 17: The US Waiting List of Patients for Organ Transplants by Organ Type: As of September 2015 (includes corresponding Graph/Chart)..............III-5 Strategic Corporate Developments III-5 Select Key Players..............III-6 B.Market Analytics..............III-9 Table 18: The US Recent Past, Current & Future Analysis for Organ Preservation Solutions Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart) III-9

Table 19: The US Historic Review for Organ Preservation Solutions Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 through 2013 (includes corresponding Graph/Chart).............. III-10

2. CANADA.............. III-11 Market Analysis.............. III-11 Table 20: Canadian Recent Past, Current & Future Analysis for Organ Preservation Solutions Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart) III-11

Table 21: Canadian Historic Review for Organ Preservation Solutions Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 through 2013 (includes corresponding Graph/Chart).............. III-12

3. EUROPE.............. III-13 A.Market Analysis.............. III-13 Current & Future Analysis..............III-13 Table 22: European Deceased Organ Donation Rates Per Million Population (PMP) by Country for 2011, 2012 & 2013 (includes corresponding Graph/Chart) III-13

Table 23: European Living Organ Donation Rates Per Million Population (PMP) by Country for 2013 (includes corresponding Graph/Chart)..............III-13

Table 24: European Single Organ Transplantations by Select Country and Organ Type: 2013 (includes corresponding Graph/Chart).............. III-14

Table 25: European Multi-Organ Transplantations by Select Country and Transplant Type: 2013 (includes corresponding Graph/Chart).............. III-15 Select Countries..............III-15 Italy.............. III-15 The United Kingdom..............III-15 Table 26: The UK Organ Donors by Type: May 2015 & May 2014 (includes corresponding Graph/Chart) III-16

Table 27: The UK Organ Transplantation by Type: 2014 Vs. 2015 (includes corresponding Graph/Chart) III-16

Table 28: The UK Active Transplant Waiting List by Organ: As of April 2014 and April 2015 (includes corresponding Graph/Chart).............. III-17 Strategic Corporate Developments III-17 Select Key Players..............III-18 B.Market Analytics..............III-19 Table 29: European Recent Past, Current & Future Analysis for Organ Preservation Solutions Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart) III-19

Table 30: European Historic Review for Organ Preservation Solutions Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 through 2013 (includes corresponding Graph/Chart).............. III-20

4. ASIA-PACIFIC.............. III-21 A.Market Analysis.............. III-21 Select Regional Markets..............III-21 Australia.............. III-21 Table 31: Australia Organ Transplantations by Organ Type: 2015 (includes corresponding Graph/Chart) III-21

Table 32: Australian Organ Transplants by State: 2015 (includes corresponding Graph/Chart) III-22 China.............. III-22 Cost Efficiency Lures Transplant Patients from Overseas III-23 India.............. III-23 Overview of Renal Transplantation III-23 Low Transplantation Expenses Boost Medical Tourism III-23 Singapore.............. III-24 Awareness Programs to Increase Living Kidney Donations in Singapore.............. III-24 Strategic Corporate Development III-24 Claris Injectables Limited (India) - A Key Player III-24 B.Market Analytics..............III-25 Table 33: Asia-Pacific Recent Past, Current & Future Analysis for Organ Preservation Solutions Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart) III-25

Table 34: Asia-Pacific Historic Review for Organ Preservation Solutions Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 through 2013 (includes corresponding Graph/Chart)..............III-26

5. REST OF WORLD.............. III-27 A.Market Analysis.............. III-27 Current & Future Analysis..............III-27 Select Regional Markets..............III-27 Latin America.............. III-27 Brazil - A Major Transplant Market III-27 The Middle East..............III-27 Kuwait - A Rapidly Emerging 'Third World' Country in Organ Transplants.............. III-27 Iran - "Kidney E-Bay"..............III-27 B.Market Analytics..............III-28 Table 35: Rest of World Recent Past, Current & Future Analysis for Organ Preservation Solutions Analyzed with Annual Sales Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart) III-28

Table 36: Rest of World Historic Review for Organ Preservation Solutions Analyzed with Annual Sales Figures in US$ Thousand for Years 2007 through 2013 (includes corresponding Graph/Chart)..............III-29

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 21

The United States (13) Europe (7) - France (2) - Germany (1) - The United Kingdom (1) - Rest of Europe (3) Asia-Pacific (Excluding Japan) (1)
Read the full report: http://www.reportlinker.com/p0209264-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker reviews, finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com


__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

Related Links

http://www.reportlinker.com

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.